Loading...
Market
Next milestone in Michael's treatment by end of 2024
4
Resolution / Starting Odds
Significant improvement • 33%
Stabilization • 33%
No improvement • 33%
Official reports and press releases from SickKids Hospital
Story
Gene Therapy Halts Progression of Rare Genetic Condition in 4-yr Old Toronto Boy Michael
Jun 28, 2024, 11:33 PM
A groundbreaking gene therapy has halted the progression of a rare genetic condition in a young boy from Toronto. The therapy, conducted at SickKids Hospital and published in Nature Medicine, involved a personalized AAV9-based gene therapy for hereditary spastic paraplegia type 50. The phase 1 trial, which included only one patient, showed that the therapy was well tolerated and led to preliminary disease stabilization within three years from diagnosis. The patient, Michael, a 4-yr old, is the son of Terry Pirovolakis, who played a significant role in making this treatment possible.
View original story
Similar markets
Full voice recovery • 25%
Improved but still hoarse • 25%
No significant improvement • 25%
Other • 25%
Walking Unassisted • 25%
Resuming Physical Activity • 25%
Returning to Work • 25%
Other • 25%
Full recovery • 25%
Partial recovery • 25%
No significant recovery • 25%
Other outcome • 25%
Over $500 million • 25%
$250 million to $500 million • 25%
Under $250 million • 25%
No debt settled • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Full Recovery • 25%
Partial Recovery • 25%
No Significant Change • 25%
Worsened Condition • 25%
Fully recovered • 25%
Minor injuries • 25%
Major injuries • 25%
Other • 25%
Full mobility restoration in a patient • 25%
Widespread clinical trials • 25%
FDA approval • 25%
None of the above • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%